Dose-dependent decrease of platelet activation and tissue factor by omega-3 polyunsaturated fatty acids in patients with advanced chronic heart failure

Thrombosis and Haemostasis

Volumn 106, Issue 3, 2011, Pages 457-465

  Moertl, Deddo ^a,b   Berger, Rudolf ^a   Hammer, Alexandra ^a   Hutuleac, Raisa ^a   Koppensteiner, Renate ^a   Kopp, Christoph W ^a   Steiner, Sabine ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Department of Internal Medicine III ^*  (Austria)

Author keywords

Fatty acids; Heart failure; Inflammation; Platelets; Tissue factor

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CD14 ANTIGEN; CD40 LIGAND; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOCOSAHEXAENOIC ACID; GLYCOPROTEIN IB ALPHA; ICOSAPENTAENOIC ACID; INTERLEUKIN 6; LOOP DIURETIC AGENT; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTIC TISSUE FACTOR; OMEGA 3 FATTY ACID; PADGEM PROTEIN; PLACEBO; PROTHROMBIN; PROTHROMBIN FRAGMENT F1.2; THROMBOPLASTIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; ANTIGEN EXPRESSION; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL INTERACTION; CLINICAL ARTICLE; CONTROLLED STUDY; DIET SUPPLEMENTATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; DRUG MEGADOSE; FEMALE; FLOW CYTOMETRY; HEART FAILURE; HEART MUSCLE ISCHEMIA; HEART RIGHT VENTRICLE EJECTION FRACTION; HUMAN; HUMAN CELL; MALE; MONOCYTE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOGENESIS; TREATMENT DURATION;

ADULT; ANTIGENS, CD14; BLOOD PLATELETS; CD40 LIGAND; CELL SEPARATION; CHRONIC DISEASE; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FATTY ACIDS, OMEGA-3; FEMALE; FLOW CYTOMETRY; HEART FAILURE; HUMANS; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; P-SELECTIN; PLATELET ACTIVATION; PLATELET GLYCOPROTEIN GPIB-IX COMPLEX; THROMBOPLASTIN;

EID: 80052308115     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH11-03-0169     Document Type: Article

References (42)

1. Chong AY, Lip GY. Viewpoint: the prothrombotic state in heart failure: a maladaptive inflammatory response? Eur J Heart Fail 2007; 9: 124-128
2. de Peuter OR, Kok WE, Torp-Pedersen C, et al. Systolic heart failure: a prothrombotic state. Semin Thromb Hemost 2009; 35: 497-504
3. Marcucci R, Gori AM, Giannotti F, et al. Markers of hypercoagulability and inflammation predict mortality in patients with heart failure. J Thromb Haemost 2006; 4: 1017-1022
4. Shantsila E, Lip GY. The endothelium and thrombotic risk in heart failure. Thromb Haemost 2009; 102: 185-187
5. Freudenberger RS, Schumaecker MM, Homma S. What is the appropriate approach to prevention of thromboembolism in heart failure? Thromb Haemost 2010; 103: 489-495
6. Tavazzi L, Maggioni AP, Marchioli R, et al. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372: 1223-1230
7. Lavie CJ, Milani RV, Mehra MR, et al. Omega-3 polyunsaturated fatty acids and cardiovascular diseases. J Am Coll Cardiol 2009; 54: 585-594
8. Di Minno MN, Tremoli E, Tufano A, et al. Exploring newer cardioprotective strategies: omega-3 fatty acids in perspective. Thromb Haemost 2010; 104: 664-680
9. Calder PC. Polyunsaturated fatty acids and inflammation. Prostaglandins Leukot Essent Fatty Acids 2006; 75: 197-202
10. Moertl D, Hammer A, Steiner S, et al. Dose-Dependent Effects of Omega-3-Polyunsaturated Fatty Acids on Systolic Left Ventricular Function, Endothelial Function, and Markers of Inflammation in Chronic Heart Failure of Non-Ischemic Origin. Am Heart J 2011; 161: 915.e1-e9.
11. Steiner S, Speidl WS, Pleiner J, et al. Simvastatin blunts endotoxin-induced tissue factor in vivo. Circulation 2005; 111: 1841-1846
12. Gibbs CR, Blann AD, Watson RD, et al. Abnormalities of hemorheological, endothelial, and platelet function in patients with chronic heart failure in sinus rhythm: effects of angiotensin-converting enzyme inhibitor and beta-blocker therapy. Circulation 2001; 103: 1746-1751
13. Chin BS, Blann AD, Gibbs CR, et al. Prognostic value of interleukin-6, plasma viscosity, fibrinogen, von Willebrand factor, tissue factor and vascular endothelial growth factor levels in congestive heart failure. Eur J Clin Invest 2003; 33: 941-948
14. Jug B, Vene N, Salobir BG, et al. Prognostic impact of haemostatic derangements in chronic heart failure. Thromb Haemost 2009; 102: 314-320
15. Chung I, Choudhury A, Patel J, et al. Soluble, platelet-bound, and total P-selectin as indices of platelet activation in congestive heart failure. Ann Med 2009; 41: 45-51
16. Lee KW, Lip GY. Effects of lifestyle on hemostasis, fibrinolysis, and platelet reactivity: a systematic review. Arch Intern Med 2003; 163: 2368-2392
17. Din JN, Harding SA, Valerio CJ, et al. Dietary intervention with oil rich fish reduces platelet-monocyte aggregation in man. Atherosclerosis 2008; 197: 290-296
18. Tuleta I, Bauriedel G, Hasenbank I, et al. Antiplatelet effects of n-3 polyunsaturated fatty acids compared with aspirin: a pilot study with whole-blood aggregometry. Thromb Res 2009; 124: 724-726
19. Larson MK, Ashmore JH, Harris KA, et al. Effects of omega-3 acid ethyl esters and aspirin, alone and in combination, on platelet function in healthy subjects. Thromb Haemost 2008; 100: 634-641
20. Cerbone AM, Cirillo F, Coppola A, et al. Persistent impairment of platelet aggregation following cessation of a short-course dietary supplementation of moderate amounts of N-3 fatty acid ethyl esters. Thromb Haemost 1999; 82: 128-133
21. von Schacky C, Weber PC. Metabolism and effects on platelet function of the purified eicosapentaenoic and docosahexaenoic acids in humans. J Clin Invest 1985; 76: 2446-2450
22. Calder PC. n-3 Fatty acids and cardiovascular disease: evidence explained and mechanisms explored. Clin Sci (Lond) 2004; 107: 1-11
23. Eschen O, Christensen JH, De Caterina R, et al. Soluble adhesion molecules in healthy subjects: a dose-response study using n-3 fatty acids. Nutr Metab Cardiovasc Dis 2004; 14: 180-185
24. Lee KW, Blann AD, Lip GY. Effects of omega-3 polyunsaturated fatty acids on plasma indices of thrombogenesis and inflammation in patients post-myocardial infarction. Thromb Res 2006; 118: 305-312
25. Eschen O, Christensen JH, MT LAR, et al. Effects of marine n-3 fatty acids on circulating levels of soluble adhesion molecules in patients with chronic heart failure. Cell Mol Biol (Noisy-le-grand) 2010; 56: 45-51
26. Michelson AD, Barnard MR, Krueger LA, et al. Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation 2001; 104: 1533-1537
27. Lievens D, Eijgelaar WJ, Biessen EA, et al. The multi-functionality of CD40L and its receptor CD40 in atherosclerosis. Thromb Haemost 2009; 102: 206-214
28. Stumpf C, Lehner C, Eskafi S, et al. Enhanced levels of CD154 (CD40 ligand) on platelets in patients with chronic heart failure. Eur J Heart Fail 2003; 5: 629-637
29. Ueland T, Aukrust P, Yndestad A, et al. Soluble CD40 ligand in acute and chronic heart failure. Eur Heart J 2005; 26: 1101-1107
30. Stumpf C, Lehner C, Raaz D, et al. Platelets contribute to enhanced MCP-1 levels in patients with chronic heart failure. Heart 2008; 94: 65-69
31. Chung I, Choudhury A, Patel J, et al. Soluble CD40L, platelet surface CD40L and total platelet CD40L in congestive heart failure: relationship to platelet volume, mass and granularity. J Intern Med 2008; 263: 313-321
32. Yan JC, Liu PJ, Du RZ, et al. Relationship between CD40 ligand expression and B type natriuretic peptide levels in patients with chronic heart failure. Clin Chim Acta 2008; 392: 17-20
33. Catellier DJ, Aleksic N, Folsom AR, et al. Atherosclerosis Risk in Communities (ARIC) Carotid MRI flow cytometry study of monocyte and platelet markers: intraindividual variability and reliability. Clin Chem 2008; 54: 1363-1371
34. Aarsetoy H, Brugger-Andersen T, Hetland O, et al. Long term influence of regular intake of high dose n-3 fatty acids on CD40-ligand, pregnancy-associated plasma protein A and matrix metalloproteinase-9 following acute myocardial infarction. Thromb Haemost 2006; 95: 329-336
35. Nieuwenhuys CM, Beguin S, Offermans RF, et al. Hypocoagulant and lipid-lowering effects of dietary n-3 polyunsaturated fatty acids with unchanged platelet activation in rats. Arterioscler Thromb Vasc Biol 1998; 18: 1480-1489
36. Vanschoonbeek K, Feijge MA, Paquay M, et al. Variable hypocoagulant effect of fish oil intake in humans: modulation of fibrinogen level and thrombin generation. Arterioscler Thromb Vasc Biol 2004; 24: 1734-1740
37. Marckmann P, Bladbjerg EM, Jespersen J. Dietary fish oil (4 g daily) and cardiovascular risk markers in healthy men. Arterioscler Thromb Vasc Biol 1997; 17: 3384-3391
38. Del Turco S, Basta G, Lazzerini G, et al. Effect of the administration of n-3 polyunsaturated fatty acids on circulating levels of microparticles in patients with a previous myocardial infarction. Haematologica 2008; 93: 892-899
39. Tremoli E, Eligini S, Colli S, et al. n-3 fatty acid ethyl ester administration to healthy subjects and to hypertriglyceridemic patients reduces tissue factor activity in adherent monocytes. Arterioscler Thromb 1994; 14: 1600-1608
40. Grundt H, Hetland O, Nilsen DW. Changes in tissue factor and activated factor XII following an acute myocardial infarction were uninfluenced by high doses of n-3 polyunsaturated fatty acids. Thromb Haemost 2003; 89: 752-759
41. Seljeflot I, Hurlen M, Arnesen H. Increased levels of soluble tissue factor during long-term treatment with warfarin in patients after an acute myocardial infarction. J Thromb Haemost 2004; 2: 726-730
42. Lindmark E, Tenno T, Siegbahn A. Role of platelet P-selectin and CD40 ligand in the induction of monocytic tissue factor expression. Arterioscler Thromb Vasc Biol 2000; 20: 2322-2328.